134 results
Search Results
2. Epstein–Barr virus, Cytomegalovirus, and Herpes Simplex-1/2 reactivations in critically ill patients with COVID-19.
- Author
-
Mattei, Alessia, Schiavoni, Lorenzo, Riva, Elisabetta, Ciccozzi, Massimo, Veralli, Roberta, Urselli, Angela, Citriniti, Vincenzo, Nenna, Antonio, Pascarella, Giuseppe, Costa, Fabio, Cataldo, Rita, Agrò, Felice Eugenio, and Carassiti, Massimiliano
- Subjects
COVID-19 ,EPSTEIN-Barr virus ,CRITICALLY ill ,CYTOMEGALOVIRUSES ,VENTILATOR-associated pneumonia - Abstract
Objectives: To assess the incidences of Herpes Simplex-1 and 2 (HSV-1, HSV-2), Cytomegalovirus (CMV), Epstein–Barr Virus (EBV) reactivations in critically ill COVID-19 patients. To determine the association between viral reactivation and in-hospital mortality, Intensive Care Unit Bloodstream infection (ICU–BSI), ventilator-associated pneumonia (VAP). Design: Observational retrospective cohort study. Setting: COVID-19 Intensive Care Unit. Patients: From November 2020 to May 2021, one hundred and twenty patients with COVID-19 severe pneumonia were enrolled and tested for HSV-1, HSV-2, CMV and EBV at the admission in ICU and weekly until discharge or death. The presence of VAP and ICU–BSI was evaluated according to clinical judgement and specific diagnostic criteria. Measurements and main results: One hundred and twenty patients were enrolled. Multiple reactivations occurred in 75/120 (63%) patients, single reactivation in 27/120 patients (23%). The most reactivated Herpesvirus was EBV, found in 78/120 (65%) patients. The multivariate analysis demonstrated that viral reactivation is a strong independent risk factor for in-hospital mortality (OR = 2.46, 95% CI 1.02–5.89), ICU–BSI (OR = 2.37, 95% CI 1.06–5.29) and VAP (OR = 2.64, 95% CI 1.20–5.82). Conclusions: Human Herpesviruses reactivations in critically ill patients with COVID-19 severe Pneumonia are associated with mortality and with a higher risk to develop both VAP and ICU–BSI. Key points: Question: The impact of Human Herpesviruses reactivations on the morbidity and mortality of COVID-19 critically ill patients is controversial. Findings: Critically ill patients with COVID-19 are at high risk for both EBV, HSV and CMV reactivations. Meanings: Further large prospective studies will be necessary to clarify if the presence of active viral replication must be considered causal agent affecting mortality or the indirect manifestation of immune paralysis in the worst patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. The CRISPR-Cas13a Gemini System for noncontiguous target RNA activation.
- Author
-
Zhao, Hongrui, Sheng, Yan, Zhang, Tenghua, Zhou, Shujun, Zhu, Yuqing, Qian, Feiyang, Liu, Meiru, Xu, Weixue, Zhang, Dengsong, and Hu, Jiaming
- Subjects
RNA ,NON-coding RNA ,GENOME editing ,CANCER diagnosis ,EPSTEIN-Barr virus ,BREAST - Abstract
Simultaneous multi-target detection and multi-site gene editing are two key factors restricting the development of disease diagnostic and treatment technologies. Despite numerous explorations on the source, classification, functional features, crystal structure, applications and engineering of CRISPR-Cas13a, all reports use the contiguous target RNA activation paradigm that only enables single-target detection in vitro and one-site gene editing in vivo. Here we propose a noncontiguous target RNA activation paradigm of Cas13a and establish a CRISPR-Cas13a Gemini System composed of two Cas13a:crRNA binary complexes, which can provide rapid, simultaneous, highly specific and sensitive detection of two RNAs in a single readout, as well as parallel dual transgene knockdown. CRISPR-Cas13a Gemini System are demonstrated in the detection of two miRNAs (miR-155 and miR-375) for breast cancer diagnosis and two small RNAs (EBER-1 and EBER-2) for Epstein-Barr virus diagnosis using multiple diagnostic platforms, including fluorescence and colorimetric-based lateral flow systems. We also show that CRISPR-Cas13a Gemini System can knockdown two foreign genes (EGFP and mCherry transcripts) in mammalian cells simultaneously. These findings suggest the potential of highly effective and simultaneous detection of multiple biomarkers and gene editing of multiple sites. CRISPR-Cas13a based methods currently use contiguous target RNA activation, which only enables single-target detection or editing. Here the authors propose a noncontiguous target RNA activation approach which can provide rapid, simultaneous and sensitive detection of two RNAs in a single readout, as well as parallel dual transgene knockdown. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Meta-analysis of the relationship between Epstein-Barr virus infection and clinicopathological features of patients with gastric carcinoma.
- Author
-
Li, ShuYing, Du, HaiJun, Wang, Zhan, Zhou, Ling, Zhao, XiaoYu, and Zeng, Yi
- Abstract
Epstein-Barr virus (EBV) infection has been causally associated with occurrence of many malignant neoplasms. EBV-encoded small RNAs (EBERs) have been detected from about 10% of gastric carcinoma tissue cells, suggesting that EBV infection is associated with the development of gastric carcinoma. The present study pooled the data from the papers concerning EBV-related gastric cancers and performed a meta-analysis of 22 research papers. Among these papers, a total of 5475 cases with gastric cancer were enrolled, of whom 411 cases were found EBV-positive, with the EBV-positive rate being 7.5%. Among the EBV-positive gastric cancer cases, the detection rate was 11.1% in males and 3.0% in females. Compared with EBV-negative gastric cancer, EBV-positive gastric cancer had less lymph node metastasis. Based on the histological typing, of the EBV-positive gastric cancers, the diffuse type was 8.1%, and intestinal type was 8.0%. The examined specimen types included stored paraffin blocks and fresh surgically removed specimens, their EBV positive rates were 7.9% and 6.5% respectively. In terms of geographical distribution, the detection rate of EBV-positive gastric cancer was 9.4% in America, 6.1% in Asia and 9.1% in Europe. Meta-analysis showed that EBV infection occurred only in gastric cancer tissue cells and was significantly associated with the patients' gender, lymph node metastases, and the location where tumor tissue generated and geographical distribution ( P<0.05), but was not significantly associated with the patients' histological types of tumor and the types of specimens ( P>0.05). These results suggested that EBV-positive gastric cancer has distinct clinicopathological features. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
5. Author Correction: The influence of human genetic variation on Epstein–Barr virus sequence diversity.
- Author
-
Rüeger, Sina, Hammer, Christian, Loetscher, Alexis, McLaren, Paul J., Lawless, Dylan, Naret, Olivier, Khanna, Nina, Bernasconi, Enos, Cavassini, Matthias, Günthard, Huldrych F., Kahlert, Christian R., Rauch, Andri, Depledge, Daniel P., Morfopoulou, Sofia, Breuer, Judith, Zdobnov, Evgeny, Fellay, Jacques, the Swiss HIV Cohort Study, Aebi-Popp, Karoline, and Anagnostopoulos, Alexia
- Subjects
EPSTEIN-Barr virus ,HUMAN genetic variation - Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Microbes translocation from oral cavity to nasopharyngeal carcinoma in patients.
- Author
-
Liao, Ying, Wu, Yan-Xia, Tang, Minzhong, Chen, Yi-Wei, Xie, Jin-Ru, Du, Yan, Wang, Tong-Min, He, Yong-Qiao, Xue, Wen-Qiong, Zheng, Xiao-Hui, Liu, Qiao-Yun, Zheng, Mei-Qi, Jia, Yi-Jing, Tong, Xia-Ting, Zhou, Ting, Li, Xi-Zhao, Yang, Da-Wei, Diao, Hua, and Jia, Wei-Hua
- Subjects
EPSTEIN-Barr virus ,NASOPHARYNX cancer ,GASTROINTESTINAL cancer ,MICROORGANISMS ,DISEASE risk factors ,NASOPHARYNX - Abstract
The presence of oral microbes in extra-oral sites is linked to gastrointestinal cancers. However, their potential ectopically colonization in the nasopharynx and impact on local cancer development remains uncertain. Our study involving paired nasopharyngeal-oral microbial samples from nasopharyngeal carcinoma (NPC) patients and controls unveils an aberrant oral-to-nasopharyngeal microbial translocation associated with increased NPC risk (OR = 4.51, P = 0.012). Thirteen species are classified as oral-translocated and enriched in NPC patients. Among these, Fusobacterium nucleatum and Prevotella intermedia are validated through culturomics and clonal strain identification. Nasopharyngeal biopsy meta-transcriptomes confirm these microbes within tumors, influencing local microenvironment and cytokine response. These microbes correlate significantly with the Epstein-Barr virus (EBV) loads in the nasopharynx, exhibiting an increased dose-response relationship. Collectively, our study identifies oral microbes migrating to the nasopharynx, infiltrating tumors, impacting microenvironments and linking with EBV infection. These results enhance our understanding of abnormal microbial communication and their roles in carcinogenesis. Oral microbes in non-oral locations are noted across various cancers. This study highlights the abnormal translocation of oral microbes to the nasopharynx, raising the risk of nasopharyngeal cancer by remodeling the tumor microenvironment and potentially influencing EBV infection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Remodeling of the ribosomal quality control and integrated stress response by viral ubiquitin deconjugases.
- Author
-
Liu, Jiangnan, Nagy, Noemi, Ayala-Torres, Carlos, Aguilar-Alonso, Francisco, Morais-Esteves, Francisco, Xu, Shanshan, and Masucci, Maria G.
- Subjects
QUALITY control ,UBIQUITIN ,UBIQUITIN ligases ,EPSTEIN-Barr virus ,VIRAL proteins ,RIBOSOMES ,PROTEASOMES - Abstract
The strategies adopted by viruses to reprogram the translation and protein quality control machinery and promote infection are poorly understood. Here, we report that the viral ubiquitin deconjugase (vDUB)—encoded in the large tegument protein of Epstein-Barr virus (EBV BPLF1)—regulates the ribosomal quality control (RQC) and integrated stress responses (ISR). The vDUB participates in protein complexes that include the RQC ubiquitin ligases ZNF598 and LTN1. Upon ribosomal stalling, the vDUB counteracts the ubiquitination of the 40 S particle and inhibits the degradation of translation-stalled polypeptides by the proteasome. Impairment of the RQC correlates with the readthrough of stall-inducing mRNAs and with activation of a GCN2-dependent ISR that redirects translation towards upstream open reading frames (uORFs)- and internal ribosome entry sites (IRES)-containing transcripts. Physiological levels of active BPLF1 promote the translation of the EBV Nuclear Antigen (EBNA)1 mRNA in productively infected cells and enhance the release of progeny virus, pointing to a pivotal role of the vDUB in the translation reprogramming that enables efficient virus production. Here, the authors show how the vDUB from the large tegument protein from the human herpes virus can reprogram translation in host cells by modulating the activity of the ribosome quality machinery and activating the integrated stress response. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Cell transformation mediated by the Epstein–Barr virus G protein-coupled receptor BILF1 is dependent on constitutive signaling.
- Author
-
Lyngaa, R., Nørregaard, K., Kristensen, M., Kubale, V., Rosenkilde, M. M., and Kledal, T. N.
- Subjects
CELL transformation ,EPSTEIN-Barr virus ,G proteins ,CELL receptors ,ENDOTHELIAL growth factors - Abstract
Epstein–Barr virus (EBV) open reading frame BILF1 encodes a seven trans-membrane (TM) G protein-coupled receptor that signals with high constitutive activity through Gα
i (Beisser et al., 2005; Paulsen et al., 2005). In this paper, the transforming potential of BILF1 is investigated in vitro in a foci formation assay using retrovirally transduced NIH3T3 cells, as well as in vivo by using nude mice. BILF1 revealed a substantial transforming potential that was dependent on constitutive signaling, as a signaling-deficient mutant completely lost its ability to transform cells in vitro, and an intermediately active triple-mutated receptor possessed an intermediate transforming potential. Furthermore, BILF1 expression induced vascular endothelial growth factor secretion in a constitutively active manner. In nude mice, BILF1 promoted tumor formation in 90% of cases, ORF74 (from Kaposi's sarcoma-associated herpes virus) in 100% of cases, whereas the signaling-deficient receptor resulted in tumor establishment in 40% of cases. These data suggest that BILF1, when expressed during EBV infection, could indeed be involved in the pathogenesis of EBV-associated diseases and malignancies. Furthermore, the correlation between receptor activity and the ability to mediate cell transformation in vitro and tumor formation in vivo supports the idea that inverse agonists for BILF1 could inhibit cell transformation and be relevant therapeutic candidates. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
9. Genetic design of an optimized packaging cell line for gene vectors transducing human B cells.
- Author
-
Hettich, E., Janz, A., Zeidler, R., Pich, D., Hellebrand, E., Weissflog, B., Moosmann, A., and Hammerschmidt, W.
- Subjects
VIRAL genetics ,CELL lines ,GENETIC vectors ,GENE therapy ,PLASMIDS - Abstract
Viral gene vectors often rely on packaging cell lines, which provide the necessary factors in trans for the formation of virus-like particles. Previously, we reported on a first-generation packaging cell line for gene vectors, which are based on the B-lymphotropic Epstein–Barr virus (EBV), a human γ-herpesvirus. This 293HEK-derived packaging cell line harbors a helper virus genome with a genetic modification that prevents the release of helper virions, but efficiently packages vector plasmids into virus-like particles with transducing capacity for human B cells. Here, we extended this basic approach towards a non-transforming, virus-free packaging cell line, which harbors an EBV helper virus genome with seven genetic alterations. In addition, we constructed a novel gene vector plasmid, which is devoid of a prokaryotic antibiotic resistance gene, and thus more suitable for in vivo applications in human gene therapy. We demonstrate in this paper that EBV-based gene vectors can be efficiently generated with this much-improved packaging cell line to provide helper virus-free gene vector stocks with transducing capacity for established human B-cell lines and primary B cells.Gene Therapy (2006) 13, 844–856. doi:10.1038/sj.gt.3302714; published online 19 January 2006 [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
10. Cytomegalovirus and Epstein–Barr virus co-infected young and middle-aged adults can have an aging-related T-cell phenotype.
- Author
-
Hofstee, Marloes I., Cevirgel, Alper, de Zeeuw-Brouwer, Mary-Lène, de Rond, Lia, van der Klis, Fiona, and Buisman, Anne-Marie
- Subjects
MIDDLE-aged persons ,YOUNG adults ,EPSTEIN-Barr virus ,IMMUNOSENESCENCE ,T cells ,AGE groups ,IMMUNOGLOBULINS - Abstract
Cytomegalovirus (CMV) is known to alter circulating effector memory or re-expressing CD45RA
+ (TemRA) T-cell numbers, but whether Epstein–Barr virus (EBV) does the same or this is amplified during a CMV and EBV co-infection is unclear. Immune cell numbers in blood of children and young, middle-aged, and senior adults (n = 336) were determined with flow cytometry, and additional multivariate linear regression, intra-group correlation, and cluster analyses were performed. Compared to non-infected controls, CMV-seropositive individuals from all age groups had more immune cell variance, and CMV+ EBV− senior adults had more late-differentiated CD4+ and CD8+ TemRA and CD4+ effector memory T-cells. EBV-seropositive children and young adults had a more equal immune cell composition than non-infected controls, and CMV− EBV+ senior adults had more intermediate/late-differentiated CD4+ TemRA and effector memory T-cells than non-infected controls. CMV and EBV co-infected young and middle-aged adults with an elevated BMI and anti-CMV antibody levels had a similar immune cell composition as senior adults, and CMV+ EBV+ middle-aged adults had more late-differentiated CD8+ TemRA, effector memory, and HLA-DR+ CD38− T-cells than CMV+ EBV− controls. This study identified changes in T-cell numbers in CMV- or EBV-seropositive individuals and that some CMV and EBV co-infected young and middle-aged adults had an aging-related T-cell phenotype. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
11. A model for the development of the tandem repeat units in the EBV ori-P region and a discussion of their possible function.
- Author
-
Karlin, Samuel and Blaisdell, B.
- Abstract
This paper presents an analysis of the repeat units of the ori-P region of the Epstein-Barr virus (EBV) genome. These repeat units are well-conserved palindromes. The pattern of these repeats, their lengths, phases, and the distribution of the relatively few substitutions are explained by a scenario that gives a reasonable course for the evolutionary development of the pattern. The scenario suggests a model for the production of an initiating 3/2 palindrome from a moderately lengthy sequence. The palindromic units are then multiplied in judicious combinations by mechanisms of unequal crossing-over events associated with some point substitutions and a few instances of slippage replication. The potential secondary structures of the two separated tandem palindromic repeat regions in ori-P are contrasted. Possible modes of binding of Epstein-Barr nuclear antigen (EBNA) 1 protein to these hairpins are discussed. A number of possibilities for the origin and development of the ori-P region in relation to viral and cellular function are considered. [ABSTRACT FROM AUTHOR]
- Published
- 1987
- Full Text
- View/download PDF
12. Deep learning model to predict Epstein–Barr virus associated gastric cancer in histology.
- Author
-
Jeong, Yeojin, Cho, Cristina Eunbee, Kim, Ji-Eon, Lee, Jonghyun, Kim, Namkug, Jung, Woon Yong, Sung, Joohon, Kim, Ju Han, Lee, Yoo Jin, Jung, Jiyoon, Pyo, Juyeon, Song, Jisun, Park, Jihwan, Moon, Kyoung Min, and Ahn, Sangjeong
- Subjects
DEEP learning ,STOMACH cancer ,EPSTEIN-Barr virus ,HEMATOXYLIN & eosin staining ,LABOR costs ,HISTOLOGY ,DECISION making - Abstract
The detection of Epstein–Barr virus (EBV) in gastric cancer patients is crucial for clinical decision making, as it is related with specific treatment responses and prognoses. Despite its importance, the limited medical resources preclude universal EBV testing. Herein, we propose a deep learning-based EBV prediction method from H&E-stained whole-slide images (WSI). Our model was developed using 319 H&E stained WSI (26 EBV positive; TCGA dataset) from the Cancer Genome Atlas, and 108 WSI (8 EBV positive; ISH dataset) from an independent institution. Our deep learning model, EBVNet consists of two sequential components: a tumor classifier and an EBV classifier. We visualized the learned representation by the classifiers using UMAP. We externally validated the model using 60 additional WSI (7 being EBV positive; HGH dataset). We compared the model's performance with those of four pathologists. EBVNet achieved an AUPRC of 0.65, whereas the four pathologists yielded a mean AUPRC of 0.41. Moreover, EBVNet achieved an negative predictive value, sensitivity, specificity, precision, and F1-score of 0.98, 0.86, 0.92, 0.60, and 0.71, respectively. Our proposed model is expected to contribute to prescreen patients for confirmatory testing, potentially to save test-related cost and labor. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1.
- Author
-
Wang, Jie, Ge, Junshang, Wang, Yian, Xiong, Fang, Guo, Jiayue, Jiang, Xianjie, Zhang, Lishen, Deng, Xiangying, Gong, Zhaojian, Zhang, Shanshan, Yan, Qijia, He, Yi, Li, Xiayu, Shi, Lei, Guo, Can, Wang, Fuyan, Li, Zheng, Zhou, Ming, Xiang, Bo, and Li, Yong
- Subjects
EPSTEIN-Barr virus ,PROGRAMMED death-ligand 1 ,MICRORNA ,STOMACH cancer ,ONCOGENIC viruses ,NASOPHARYNX cancer - Abstract
Epstein-Barr virus (EBV) is reportedly the first identified human tumor virus, and is closely related to the occurrence and development of nasopharyngeal carcinoma (NPC), gastric carcinoma (GC), and several lymphomas. PD-L1 expression is elevated in EBV-positive NPC and GC tissues; however, the specific mechanisms underlying the EBV-dependent promotion of PD-L1 expression to induce immune escape warrant clarification. EBV encodes 44 mature miRNAs. In this study, we find that EBV-miR-BART11 and EBV-miR-BART17-3p upregulate the expression of PD-L1 in EBV-associated NPC and GC. Furthermore, EBV-miR-BART11 targets FOXP1, EBV-miR-BART17-3p targets PBRM1, and FOXP1 and PBRM1 bind to the enhancer region of PD-L1 to inhibit its expression. Therefore, EBV-miR-BART11 and EBV-miR-BART17-3p inhibit FOXP1 and PBRM1, respectively, and enhance the transcription of PD-L1 (CD274, http://www.ncbi.nlm.nih.gov/gene/29126), resulting in the promotion of tumor immune escape, which provides insights into potential targets for EBV-related tumor immunotherapy. Epstein-Barr virus (EBV)-encoded latent genes are reported to regulate PD-L1 expression to promote immune escape. Here, the authors show that EBV-encoded miRNAs EBV-miR-BART11 and EBV-miR-BART17-3p upregulate PD-L1 expression in nasopharyngeal carcinoma and gastric cancer by targeting FOXP1 and PBRM1. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. The three-dimensional structure of Epstein-Barr virus genome varies by latency type and is regulated by PARP1 enzymatic activity.
- Author
-
Morgan, Sarah M., Tanizawa, Hideki, Caruso, Lisa Beatrice, Hulse, Michael, Kossenkov, Andrew, Madzo, Jozef, Keith, Kelsey, Tan, Yinfei, Boyle, Sarah, Lieberman, Paul M., and Tempera, Italo
- Subjects
EPSTEIN-Barr virus ,VIRAL genomes ,GENE expression ,BINDING sites ,POLY(ADP-ribose) polymerase ,GENOMES - Abstract
Epstein-Barr virus (EBV) persists in human B-cells by maintaining its chromatinized episomes within the nucleus. We have previously shown that cellular factor Poly [ADP-ribose] polymerase 1 (PARP1) binds the EBV genome, stabilizes CTCF binding at specific loci, and that PARP1 enzymatic activity correlates with maintaining a transcriptionally active latency program. To better understand PARP1's role in regulating EBV latency, here we functionally characterize the effect of PARP enzymatic inhibition on episomal structure through in situ HiC mapping, generating a complete 3D structure of the EBV genome. We also map intragenomic contact changes after PARP inhibition to global binding of chromatin looping factors CTCF and cohesin across the EBV genome. We find that PARP inhibition leads to fewer total unique intragenomic interactions within the EBV episome, yet new chromatin loops distinct from the untreated episome are also formed. This study also illustrates that PARP inhibition alters gene expression at the regions where chromatin looping is most effected. We observe that PARP1 inhibition does not alter cohesin binding sites but does increase its frequency of binding at those sites. Taken together, these findings demonstrate that PARP has an essential role in regulating global EBV chromatin structure and latent gene expression. Genome folding in the nucleus plays an important role in regulating gene expression. Here the authors show that 3D genome architecture also plays an important role for gene expression adaptability for the Epstein-Barr Virus (EBV), a virus that is associated with cancer. They also observe major changes in the fold of the EBV chromosome between silent and transcriptional active viral genomes. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. A deep learning model and human-machine fusion for prediction of EBV-associated gastric cancer from histopathology.
- Author
-
Zheng, Xueyi, Wang, Ruixuan, Zhang, Xinke, Sun, Yan, Zhang, Haohuan, Zhao, Zihan, Zheng, Yuanhang, Luo, Jing, Zhang, Jiangyu, Wu, Hongmei, Huang, Dan, Zhu, Wenbiao, Chen, Jianning, Cao, Qinghua, Zeng, Hong, Luo, Rongzhen, Li, Peng, Lan, Lilong, Yun, Jingping, and Xie, Dan
- Subjects
DEEP learning ,STOMACH cancer ,EPSTEIN-Barr virus ,IMMUNE checkpoint inhibitors ,CONVOLUTIONAL neural networks ,HISTOPATHOLOGY ,CANCER patients - Abstract
Epstein–Barr virus-associated gastric cancer (EBVaGC) shows a robust response to immune checkpoint inhibitors. Therefore, a cost-efficient and accessible tool is needed for discriminating EBV status in patients with gastric cancer. Here we introduce a deep convolutional neural network called EBVNet and its fusion with pathologists for predicting EBVaGC from histopathology. The EBVNet yields an averaged area under the receiver operating curve (AUROC) of 0.969 from the internal cross validation, an AUROC of 0.941 on an external dataset from multiple institutes and an AUROC of 0.895 on The Cancer Genome Atlas dataset. The human-machine fusion significantly improves the diagnostic performance of both the EBVNet and the pathologist. This finding suggests that our EBVNet could provide an innovative approach for the identification of EBVaGC and may help effectively select patients with gastric cancer for immunotherapy. Epstein–Barr virus-associated gastric cancer shows a robust response to immune checkpoint inhibitors. Here the authors introduce a deep convolutional neural network and its fusion with pathologists for predicting it from histopathology. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Circulating microbial content in myeloid malignancy patients is associated with disease subtypes and patient outcomes.
- Author
-
Woerner, Jakob, Huang, Yidi, Hutter, Stephan, Gurnari, Carmelo, Sánchez, Jesús María Hernández, Wang, Janet, Huang, Yimin, Schnabel, Daniel, Aaby, Michael, Xu, Wanying, Thorat, Vedant, Jiang, Dongxu, Jha, Babal K., Koyuturk, Mehmet, Maciejewski, Jaroslaw P., Haferlach, Torsten, and LaFramboise, Thomas
- Subjects
TREATMENT effectiveness ,HEMATOLOGIC malignancies ,MYELODYSPLASTIC syndromes ,EPSTEIN-Barr virus ,MACHINE learning ,BRUGADA syndrome - Abstract
Although recent work has described the microbiome in solid tumors, microbial content in hematological malignancies is not well-characterized. Here we analyze existing deep DNA sequence data from the blood and bone marrow of 1870 patients with myeloid malignancies, along with healthy controls, for bacterial, fungal, and viral content. After strict quality filtering, we find evidence for dysbiosis in disease cases, and distinct microbial signatures among disease subtypes. We also find that microbial content is associated with host gene mutations and with myeloblast cell percentages. In patients with low-risk myelodysplastic syndrome, we provide evidence that Epstein-Barr virus status refines risk stratification into more precise categories than the current standard. Motivated by these observations, we construct machine-learning classifiers that can discriminate among disease subtypes based solely on bacterial content. Our study highlights the association between the circulating microbiome and patient outcome, and its relationship with disease subtype. Circulating microbiome has been very little studied for blood malignancies. Here, the authors show specific microbiome signatures in the blood are associated with different types of myeloid malignancies and specific genetic mutations. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Occupational cancer in Britain.
- Author
-
Slack, Rebecca, Young, Charlotte, and Rushton, Lesley
- Subjects
OCCUPATIONAL diseases ,PHARYNGEAL cancer ,EPSTEIN-Barr virus ,RESPIRATORY infections ,CARCINOGENS - Abstract
The article discusses occupational nasopharengeal and sinonasal cancers in Great Britain. Causal factors for these cancers include Epstein-Barr virus infection, consumption of preserved food and respiratory tract infections. Formaldehyde, wood dusts, leather dust and nickel are considered as carcinogens.
- Published
- 2012
- Full Text
- View/download PDF
18. Mitogenic activity of Epstein-Barr virus-encoded BARF1 protein.
- Author
-
Sall, Alhousseynou, Caserta, Sophie, Jolicoeur, Pierre, Franqueville, Laure, de Turenne-Tessier, Mireille, and Ooka, Tadamasa
- Subjects
- *
EPSTEIN-Barr virus , *PROTEINS , *MITOGENS , *EPITHELIAL cells , *FIBROBLASTS , *CELL cycle , *TETRACYCLINE - Abstract
We previously reported that BARF1 gene has either an immortalizing effect, when expressed in primary primate epithelial cells, or a malignant transforming activity, when expressed in established and nontumoral rodent fibroblast or human B-cell lines. As predicted from sequence analysis, we found that BARF1 coded protein can be secreted from different cell lines, among them BARF1-transfected Balb/c3T3 rodent fibroblasts. Thus, as an initial step to clarify BARF1 oncogenic functions, we investigated whether the secreted form of BARF1 protein can activate the cell cycle as a growth factor. Since efficient BARF1 expression could be obtained from 293-tTA cells infected with a tetracycline-regulatable recombinant adenovirus, secreted BARF1 product could be purified from the culture medium of such cells by ammonium sulfate precipitation, ion exchange chromotography and sucrose gradient sedimentation. We describe in this paper that addition of a purified product of secreted BARF1 protein to serum-free culture medium of Balb/c3T3 rodent fibroblasts, human Louckes B-cell line and primary monkey kidney epithelial cells resulted in a cell cycle activation that was inhibited by affinity-purified anti-BARF1 antibody. Our demonstration of a specific stimulation of cell cycle in vitro by BARF1 secreted product suggests that this EBV-encoded BARF1 protein could act as a growth factor in vivo.Oncogene (2004) 23, 4938-4944. doi:10.1038/sj.onc.1207607 Published online 5 April 2004 [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
19. Kaposi's sarcoma-associated herpesvirus T cell responses in HIV seronegative individuals from rural Uganda.
- Author
-
Nalwoga, Angela, Roshan, Romin, Moore, Kyle, Marshall, Vickie, Miley, Wendell, Labo, Nazzarena, Nakibuule, Marjorie, Cose, Stephen, Rochford, Rosemary, Newton, Robert, and Whitby, Denise
- Subjects
KAPOSI'S sarcoma-associated herpesvirus ,HERPESVIRUSES ,EPSTEIN-Barr virus ,MONONUCLEAR leukocytes ,T cells - Abstract
T cell responses to Kaposi's sarcoma-associated herpesvirus (KSHV) are likely essential in the control of KSHV infection and protection from associated disease, but remain poorly characterised. KSHV prevalence in rural Uganda is high at >90%. Here we investigate IFN- γ T cell responses to the KSHV proteome in HIV-negative individuals from a rural Ugandan population. We use an ex-vivo IFN- γ ELISpot assay with overlapping peptide pools spanning 83 KSHV open reading frames (ORF) on peripheral blood mononuclear cells (PBMC) from 116 individuals. KSHV-specific T cell IFN- γ responses are of low intensity and heterogeneous, with no evidence of immune dominance; by contrast, IFN- γ responses to Epstein–Barr virus, Cytomegalovirus and influenza peptides are frequent and intense. Individuals with KSHV DNA in PBMC have higher IFN- γ responses to ORF73 (p = 0.02) and lower responses to K8.1 (p = 0.004) when compared with those without KSHV DNA. In summary, we demonstrate low intensity, heterogeneous T cell responses to KSHV in immune-competent individuals. The T cell response to Kaposi sarcoma-associated herpesvirus is critical to controlling infection and immunopathology but has been poorly explored in immunocompetent patients. Here the authors characterise the T cell response to the Kaposi sarcoma-associated herpesvirus proteome in immunocompetent patients from rural Uganda. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Uncovering early events in primary Epstein-Barr virus infection using a rabbit model.
- Author
-
Reguraman, Narendran, Hassani, Asma, Philip, Pretty, and Khan, Gulfaraz
- Subjects
EPSTEIN-Barr virus ,EPSTEIN-Barr virus diseases ,GERMINAL centers ,ANIMAL tagging ,INFECTION ,RABBITS - Abstract
Epstein-Barr virus (EBV) is an oncogenic herpesvirus implicated in the pathogenesis of several malignant and non-malignant conditions. However, a number of fundamental aspects about the biology of EBV and the mechanism(s) by which this virus induces pathology remain unknown. One major obstacle has been the lack of a suitable animal model for EBV infection. In this study, using our recently established rabbit model of EBV infection, we examined the early events following primary EBV infection. We show that, both immunocompetent and immunosuppressed animals were readily susceptible to EBV infection. However, immunosuppressed animals showed marked splenomegaly and widespread infection. Following EBV infection, the virus primarily targeted naïve IgM
+ , CD20+ , CD21+ and CD79a+ B cells. Infected cells expressed varying sets of viral latent/lytic gene products. Notably, co-expression of latent and lytic proteins in the same cell was not observed. Infected cells in type 0/1 latency (EBERs+ ), were small and proliferating (Ki67+ ). By contrast, cells in type 2/3 latency (LMP1+ ), were large, non-proliferating (Ki-67− ) and p53+ . Although infected B-cells were widely present in splenic follicles, they did not express germinal center marker, BCL-6. Taken together, this study shows for the first time, some of the early events following primary EBV infection. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
21. Clinical aspects of neuroAIDS.
- Author
-
Everall, I. and Levy, R.
- Subjects
- *
VIROLOGY , *HIV infections , *ANTIRETROVIRAL agents , *AZIDOTHYMIDINE , *CEREBROSPINAL fluid , *EPSTEIN-Barr virus , *LYMPHOMAS , *CONFERENCES & conventions - Abstract
Presents papers on the clinical aspects of neuroAIDS, which were presented at the Fourth International Symposium on NeuroVirology and at the Tenth Conference on Neuroscience of HIV Infection. Anti-HIV activity; Effect of highly active antiretroviral therapy on neurological functioning; Selective accumulation of AZT, 3TC and Indinavir in the ventricular cerebrospinal fluid; Cerebral bioavailability of anti-retroviral nucleoside analogs; Epstein-Barr virus DNA load in cerebrospinal fluid of patients with AIDS-related lymphomas.
- Published
- 2002
- Full Text
- View/download PDF
22. EBNA1 inhibitors have potent and selective antitumor activity in xenograft models of Epstein–Barr virus-associated gastric cancer.
- Author
-
Soldan, Samantha S., Anderson, Emma M., Frase, Drew M., Zhang, Yue, Caruso, Lisa B., Wang, Yin, Deakyne, Julianna S., Gewurz, Benjamin E., Tempera, Italo, Lieberman, Paul M., and Messick, Troy E.
- Subjects
STOMACH cancer ,GENETIC regulation ,VIRAL genes ,EPSTEIN-Barr virus ,GENE expression - Abstract
Background and aims: Epstein–Barr virus (EBV)-associated gastric carcinoma (EBVaGC) is the most common EBV-associated cancer and accounts for ~ 10% of all gastric cancers (GC). Epstein–Barr virus nuclear antigen 1 (EBNA1), which is critical for the replication and maintenance of the EBV latent genome, is consistently expressed in all EBVaGC tumors. We previously developed small molecule inhibitors of EBNA1. In this study, we investigated the efficacy and selectivity of an EBNA1 inhibitor in cell-based and animal xenograft models of EBV-positive and EBV-negative gastric carcinoma. Methods: We tested the potency of an EBNA1 inhibitor, VK-1727, in vitro and in xenograft studies, using EBV-positive (SNU719 and YCCEL1) and EBV-negative (AGS and MKN74) GC cell lines. After treatment, we analyzed cell viability, proliferation, and RNA expression of EBV genes by RT-qPCR. Results: Treatment with VK-1727 selectively inhibits cell cycle progression and proliferation in vitro. In animal studies, treatment with an EBNA1 inhibitor resulted in a significant dose-dependent decrease in tumor growth in EBVaGC xenograft models, but not in EBV-negative GC xenograft studies. Gene expression analysis revealed that short term treatment in cell culture tended towards viral gene activation, while long-term treatment in animal xenografts showed a significant decrease in viral gene expression. Conclusions: EBNA1 inhibitors are potent and selective inhibitors of cell growth in tissue culture and animal models of EBV-positive GC. Long-term treatment with EBNA1 inhibitors may lead to loss of EBV in mouse xenografts. These results suggest that pharmacological targeting of EBNA1 may be an effective strategy to treat patients with EBVaGC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. Metagenomic Next-Generation Sequencing for the Diagnosis of Pneumocystis jirovecii Pneumonia in Non-HIV-Infected Patients: A Retrospective Study.
- Author
-
Jiang, Juan, Bai, Lu, Yang, Wei, Peng, Wenzhong, An, Jian, Wu, Yanhao, Pan, Pinhua, and Li, Yuanyuan
- Subjects
NUCLEOTIDE sequencing ,PNEUMOCYSTIS pneumonia ,BRONCHOALVEOLAR lavage ,DIAGNOSIS ,EPSTEIN-Barr virus ,RETROSPECTIVE studies - Abstract
Introduction: This study aimed to evaluate the utility of metagenomic next-generation sequencing (mNGS) for the diagnosis of Pneumocystis jirovecii pneumonia (PJP) in non-human immunodeficiency virus-infected patients. Methods: We conducted a retrospective study. A total of 60 non-human immunodeficiency virus-infected PJP patients and 134 patients diagnosed with non-PJP pneumonia were included. P. jirovecii and other co-pathogens identified by mNGS in bronchoalveolar lavage fluid and/or blood samples were analyzed. Using clinical composite diagnosis as the reference standard, we compared the diagnostic performance of mNGS in PJP with conventional methods, including Gomori methenamine silver staining and serum (1,3)-β-d-glucan. Modifications of antimicrobial treatment for PJP patients after the report of mNGS results were also reviewed. Results: mNGS reached a sensitivity of 100% in diagnosing PJP, which was remarkably higher than Gomori methenamine silver staining (25.0%) and serum (1,3)-β-d-glucan (67.4%). The specificity of mNGS (96.3%) significantly surpassed serum (1,3)-β-d-glucan (81.4%). Simultaneous mNGS of bronchoalveolar lavage fluid and blood samples was performed in 21 out of 60 PJP patients, and it showed a concordance rate of 100% in detecting P. jirovecii. Besides, mNGS showed good performance in identifying co-pathogens of PJP patients, among which cytomegalovirus and Epstein-Barr virus were most commonly seen. Initial antimicrobial treatment was modified in 71.7% of PJP patients after the report of mNGS results. Conclusion: mNGS is a useful diagnostic tool with good performance for the diagnosis of PJP and the detection of co-pathogens. mNGS of bronchoalveolar lavage fluid and/or blood samples is suggested in patients with presumptive diagnosis of PJP. Blood samples may be a good alternative to bronchoalveolar lavage fluid for mNGS when bronchoscopic examination is not feasible. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. A comprehensive risk score for effective risk stratification and screening of nasopharyngeal carcinoma.
- Author
-
Zhou, Xiang, Cao, Su-Mei, Cai, Yong-Lin, Zhang, Xiao, Zhang, Shanshan, Feng, Guo-Fei, Chen, Yufeng, Feng, Qi-Sheng, Chen, Yijun, Chang, Ellen T., Liu, Zhonghua, Adami, Hans-Olov, Liu, Jianjun, Ye, Weimin, Zhang, Zhe, Zeng, Yi-Xin, and Xu, Miao
- Subjects
NASOPHARYNX cancer ,EPSTEIN-Barr virus ,SECONDARY prevention ,HUMAN genetics ,ODDS ratio ,CONFIDENCE intervals - Abstract
Using Epstein-Barr virus (EBV)-based markers to screen populations at high risk for nasopharyngeal carcinoma (NPC) is an attractive preventive approach. Here, we develop a comprehensive risk score (CRS) that combines risk effects of EBV and human genetics for NPC risk stratification and validate this CRS within an independent, population-based dataset. Comparing the top decile with the bottom quintile of CRSs, the odds ratio of developing NPC is 21 (95% confidence interval: 12–37) in the validation dataset. When combining the top quintile of CRS with EBV serology tests currently used for NPC screening in southern China, the positive prediction value of screening increases from 4.70% (serology test alone) to 43.24% (CRS plus serology test). By identifying individuals at a monogenic level of NPC risk, this CRS approach provides opportunities for personalized risk prediction and population screening in endemic areas for the early diagnosis and secondary prevention of NPC. Epstein-Barr virus (EBV) is associated with high risk for nasopharyngeal carcinoma (NPC). Here, the authors develop a comprehensive risk score that combines risk effects of EBV and human genetics for NPC risk stratification. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. Phase separation of Epstein-Barr virus EBNA2 protein reorganizes chromatin topology for epigenetic regulation.
- Author
-
Yang, Yiting, Ye, Xidong, Dai, Ranran, Li, Zhaoqiang, Zhang, Yan, Xue, Wei, Zhu, Yongchang, Feng, Delong, Qin, Litao, Wang, Xin, Lei, Bo, Liao, Shixiu, and Hao, Bingtao
- Subjects
EPSTEIN-Barr virus ,VIRAL genes ,CHROMATIN ,EPIGENETICS ,ACETYLATION - Abstract
Epstein-Barr virus nuclear antigen 2 (EBNA2) is a transactivator of viral and cellular gene expression, which plays a critical role in the Epstein-Barr virus-associated diseases. It was reported that EBNA2 regulates gene expression by reorganizing chromatin and manipulating epigenetics. Recent studies showed that liquid-liquid phase separation plays an essential role in epigenetic and transcriptional regulation. Here we show that EBNA2 reorganized chromatin topology to form accessible chromatin domains (ACDs) of the host genome by phase separation. The N-terminal region of EBNA2, which is necessary for phase separation, is sufficient to induce ACDs. The C-terminal domain of EBNA2 promotes the acetylation of accessible chromatin regions by recruiting histone acetylase p300 to ACDs. According to these observations, we proposed a model of EBNA2 reorganizing chromatin topology for its acetylation through phase separation to explain the mechanism of EBNA2 hijacking the host genome by controlling its epigenetics. Yang et al find that phase separation of the Epstein-Barr virus nuclear antigen 2 (EBNA2) is involved in the formation of accessible chromatin domains of the host genome. They also find that EBNA2 recruits histone acetyltransferase to promote histone acetylation on accessible chromatin regions and regulate gene expression and that these two functions are performed by the N- and Cterminus respectively. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. Positive Epstein–Barr virus detection in coronavirus disease 2019 (COVID-19) patients.
- Author
-
Chen, Ting, Song, Jiayi, Liu, Hongli, Zheng, Hongmei, and Chen, Changzheng
- Subjects
EPSTEIN-Barr virus ,COVID-19 pandemic ,SEROLOGY ,MIXED infections ,INFLAMMATION - Abstract
The objective of this study was to detect the Epstein–Barr virus (EBV) coinfection in coronavirus disease 2019 (COVID-19). In this retrospective single-center study, we included 67 COVID-19 patients with onset time within 2 weeks in Renmin Hospital of Wuhan University from January 9 to February 29, 2020. Patients were divided into EBV/SARS-CoV-2 coinfection group and SARS-CoV-2 infection alone group according to the serological results of EBV, and the characteristics differences between the two groups were compared. The median age was 37 years, with 35 (52.2%) females. Among these COVID-19 patients, thirty-seven (55.2%) patients were seropositive for EBV viral capsid antigen (VCA) IgM antibody. EBV/SARS-CoV-2 coinfection patients had a 3.09-fold risk of having a fever symptom than SARS-CoV-2 infection alone patients (95% CI 1.11–8.56; P = 0.03). C-reactive protein (CRP) (P = 0.02) and the aspartate aminotransferase (AST) (P = 0.04) in EBV/SARS-CoV-2 coinfection patients were higher than that in SARS-CoV-2 infection alone patients. EBV/SARS-CoV-2 coinfection patients had a higher portion of corticosteroid use than the SARS-CoV-2 infection alone patients (P = 0.03). We find a high incidence of EBV coinfection in COVID-19 patients. EBV/SARS-CoV-2 coinfection was associated with fever and increased inflammation. EBV reactivation may associated with the severity of COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. Evolution of antibody titres against Epstein–Barr virus and human herpesvirus 6A/B and expression of multiple sclerosis-associated retrovirus in the serum of pregnant multiple sclerosis patients.
- Author
-
Pérez-Pérez, Silvia, Cuello, Juan Pablo, Martínez-Ginés, Marisa, Pardo-Rodríguez, Beatriz, García-Domínguez, José Manuel, Domínguez-Mozo, María Inmaculada, Lozano-Ros, Alberto, García-Martínez, María Ángel, Higueras, Yolanda, Meldaña-Rivera, Ariana, Goicochea-Briceño, Haydee, Tejeda-Velarde, Amalia, Fernández-Velasco, Jose Ignacio, Medina, Silvia, Arroyo, Rafael, Villar, Luisa María, and Álvarez-Lafuente, Roberto
- Subjects
EPSTEIN-Barr virus ,MULTIPLE sclerosis ,RETROVIRUSES ,MESSENGER RNA ,GENE expression - Abstract
Epstein–Barr virus (EBV), human herpesvirus 6A/B (HHV-6A/B) and multiple sclerosis (MS)-associated retrovirus (MSRV) have been described as possible MS triggers. We analysed antibody titres against EBV and HHV-6, and MSRV envelope (env) mRNA expression, in the serum of pregnant multiple sclerosis patients (P-MS) to study their possible link to the clinical activity of MS during pregnancy and postpartum and their possible role as relapse predictors. For that purpose, serum samples were collected from 71 pregnant women (50 pregnant MS and 21 pregnant healthy controls—P-HC) during pregnancy and postpartum. Relating to antibody titres, IgM antibody titres against HHV-6A/B were significantly higher in P-MS than in P-HC both in each pregnancy trimester and in the postpartum period. Moreover, IgM antibody titres against HHV-6A/B were higher in P-MS who suffered a relapse during the postpartum. Regarding MSRV env mRNA expression, the prevalence in the first trimester of pregnancy was significantly higher in P-MS who suffered relapses during pregnancy. Summing it up, high IgM antibody titres against HHV-6A/B and MSRV env mRNA expression during the first trimester of pregnancy could act as relapse predictors for the gestation/postpartum periods. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
28. The influence of human genetic variation on Epstein–Barr virus sequence diversity.
- Author
-
Rüeger, Sina, Hammer, Christian, Loetscher, Alexis, McLaren, Paul J., Lawless, Dylan, Naret, Olivier, Depledge, Daniel P., Morfopoulou, Sofia, Breuer, Judith, Zdobnov, Evgeny, Fellay, Jacques, the Swiss HIV Cohort Study, Aebi-Popp, Karoline, Anagnostopoulos, Alexia, Battegay, Manuel, Bernasconi, Enos, Böni, Jürg, Braun, Dominique, Bucher, Heiner, and Calmy, Alexandra
- Subjects
HUMAN genetic variation ,EPSTEIN-Barr virus ,VIRAL genomes ,T cells ,VIREMIA - Abstract
Epstein–Barr virus (EBV) is one of the most common viruses latently infecting humans. Little is known about the impact of human genetic variation on the large inter-individual differences observed in response to EBV infection. To search for a potential imprint of host genomic variation on the EBV sequence, we jointly analyzed paired viral and human genomic data from 268 HIV-coinfected individuals with CD4 + T cell count < 200/mm
3 and elevated EBV viremia. We hypothesized that the reactivated virus circulating in these patients could carry sequence variants acquired during primary EBV infection, thereby providing a snapshot of early adaptation to the pressure exerted on EBV by the individual immune response. We searched for associations between host and pathogen genetic variants, taking into account human and EBV population structure. Our analyses revealed significant associations between human and EBV sequence variation. Three polymorphic regions in the human genome were found to be associated with EBV variation: one at the amino acid level (BRLF1:p.Lys316Glu); and two at the gene level (burden testing of rare variants in BALF5 and BBRF1). Our findings confirm that jointly analyzing host and pathogen genomes can identify sites of genomic interactions, which could help dissect pathogenic mechanisms and suggest new therapeutic avenues. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
29. PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms.
- Author
-
Nakano, Hiroshi, Saito, Motonobu, Nakajima, Shotaro, Saito, Katsuharu, Nakayama, Yuko, Kase, Koji, Yamada, Leo, Kanke, Yasuyuki, Hanayama, Hiroyuki, Onozawa, Hisashi, Okayama, Hirokazu, Fujita, Shotaro, Sakamoto, Wataru, Saze, Zenichiro, Momma, Tomoyuki, Mimura, Kosaku, Ohki, Shinji, Goto, Akiteru, and Kono, Koji
- Subjects
STOMACH cancer ,PROTEIN expression ,EPIGENETICS ,EPSTEIN-Barr virus ,TUMOR microenvironment - Abstract
Epstein-Barr virus-positive gastric cancer [EBV (+) GC] is a distinct GC subtype with unique genetic and epigenetic aberrations. Here, we examined resected GC samples and publicly available microarray data and The Cancer Genome Atlas (TCGA) database to identify the mechanism underlying overexpression of PD-L1 in EBV (+) GC. We found that high levels of PD-L1 overexpression in EBV (+) GC were caused by focal amplification of CD274. By contrast, relatively high expression of PD-L1 in tumor tissue and infiltrating immune cells correlated with CD8 lymphocyte infiltration and IFN-γ expression via IRF3 activation. Since we reported previously that PD-L1 expression is associated both with the presence of CD8 T cells in the tumor microenvironment and with IFN-γ expression in GC, we examined a database to see whether IFN-γ-associated overexpression of PD-L1 plays a significant role in EBV (+) GC. Immunohistochemical staining showed that expression of the IRF3 signature in clinical GC samples was higher in EBV (+) than in EBV (−) cases. The data presented herein reveal a unique dual mechanism underlying PD-L1 overexpression in EBV (+) GC: high focal amplification of CD274 or IFN-γ-mediated signaling via activation of IRF3. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy.
- Author
-
Lechner, Matt, Schartinger, Volker H., Steele, Christopher D., Nei, Wen Long, Ooft, Marc Lucas, Schreiber, Liesa-Marie, Pipinikas, Christodoulos P., Chung, Grace Tin-Yun, Chan, Yuk Yu, Wu, Feng, To, Ka-Fai, Tsang, Chi Man, Pearce, Wayne, Morelli, Daniele, Philpott, Martin, Masterson, Liam, Nibhani, Reshma, Wells, Graham, Bell, Christopher G., and Koller, Julia
- Subjects
EPSTEIN-Barr virus diseases ,SOMATOSTATIN receptors ,NASOPHARYNX cancer ,NASOPHARYNX ,MEMBRANE proteins ,EPSTEIN-Barr virus - Abstract
Nasopharyngeal cancer (NPC), endemic in Southeast Asia, lacks effective diagnostic and therapeutic strategies. Even in high-income countries the 5-year survival rate for stage IV NPC is less than 40%. Here we report high somatostatin receptor 2 (SSTR2) expression in multiple clinical cohorts comprising 402 primary, locally recurrent and metastatic NPCs. We show that SSTR2 expression is induced by the Epstein–Barr virus (EBV) latent membrane protein 1 (LMP1) via the NF-κB pathway. Using cell-based and preclinical rodent models, we demonstrate the therapeutic potential of SSTR2 targeting using a cytotoxic drug conjugate, PEN-221, which is found to be superior to FDA-approved SSTR2-binding cytostatic agents. Furthermore, we reveal significant correlation of SSTR expression with increased rates of survival and report in vivo uptake of the SSTR2-binding
68 Ga-DOTA-peptide radioconjugate in PET-CT scanning in a clinical trial of NPC patients (NCT03670342). These findings reveal a key role in EBV-associated NPC for SSTR2 in infection, imaging, targeted therapy and survival. Nasopharyngeal carcinoma (NPC) lacks effective diagnostic and therapeutic strategies, in particular at advanced stages. Here, the authors show that expression of the somatostatin receptor 2 is induced by Epstein-Barr virus in NPC and has a key role in the diagnosis, imaging, targeted therapies and prognosis of NPC. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
31. Association of Epstein-Barr virus infection with peripheral immune parameters and clinical outcome in advanced nasopharyngeal carcinoma.
- Author
-
Tao, Dan, Zhang, Ningning, Huang, Qingqing, Ge, Chuang, Li, Qicheng, Li, Shujie, Weng, Kegui, Guo, Qishuai, Sui, Jiangdong, Wang, Can, Zhang, Xin, and Wang, Ying
- Subjects
EPSTEIN-Barr virus ,NASOPHARYNX cancer ,KILLER cells ,LIVER metastasis ,REGRESSION analysis - Abstract
The purpose of this study was to investigate the association of Epstein-Barr virus (EBV) with peripheral blood immune cell counts and clinical outcomes in advanced nasopharyngeal carcinoma (NPC) patients. In a retrospective design, 146 patients with NPC at stage IV were enrolled in this study. The association of EBV status with peripheral blood immune cell counts, distant metastases, and long-term survival in patients with advanced NPC were determined. Eighty-seven (59.6%) of all patients were positive for EBV. Compared with patients with normal NK cell count, patients with lower NK cell count showed a significantly lower EBV viral load (median: 614.0 vs. 2190.0 copies/mL, P = 0.024). EBV-positive patients showed a significantly higher incidence of liver metastasis than EBV-negative patients (32.6% vs. 23.7%, P = 0.021). Multi-variant regression analysis showed that EBV infection was independently associated with liver metastasis (OR: 2.33, P = 0.043). EBV positive patients showed a significantly worse PFS (P = 0.001) and OS (P = 0.001) than EBV negative patients. Multivariate Cox regression analysis revealed that EBV infection was independently associated with a worse PFS (HR: 1.94, P = 0.003), and OS (HR: 2.12, P = 0.014) in advanced NPC. In conclusion, EBV infection is associated with a high risk of liver metastasis and is also an independent negative predictor for PFS and OS in patients with advanced NPC. EBV infection is associated with lower CD8% and higher NK%, while lower NK cell count is associated with lower EBV viral load. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
32. Epstein-Barr virus sustains tumor killers.
- Author
-
O'Reilly, Richard J.
- Subjects
- *
T cells , *IMMUNOTHERAPY , *IMMUNE response , *IMMUNE system , *EPSTEIN-Barr virus - Abstract
The article comments on a paper by M. A. Pule and colleagues about a strategy for T cell immunotherapy that takes advantage of the sustained immune response. According to the author, the strategy comes from the unique interactions of Epstein-Barr virus with the immune system. He adds that retroviral vectors encoding a tumor-specific chimeric antigen receptor (CAR) consisting of an antibody-derived single-chain variable fragment and an intracellular CD3 domain were used.
- Published
- 2008
- Full Text
- View/download PDF
33. Vaccine development/Prion disease/Viral-induced tumours.
- Author
-
Levy, R., Riesner, D., and Khalili, K.
- Subjects
- *
VIROLOGY , *HIV infections , *VIRAL replication , *AIDS vaccines , *PRION diseases , *EPSTEIN-Barr virus , *CONFERENCES & conventions - Abstract
Presents papers on vaccine development. prion disease and viral-induced tumors, which were presented at the Fourth International Symposium on NeuroVirology and at the Tenth Conference on Neuroscience of HIV Infection. Conditional virus replication as an approach to a safe live-attenuated HIV-1 vaccine; Immunobiology of prion diseases; Epstein Barr virus and cancer; Effect of tricyclic compounds quinacrine and chlorpromazine on prion infectivity; IGF-I receptor signaling system in JCV T-antigen-induced primitive neuroectodermal tumors; Studies on medulloblastomas.
- Published
- 2002
- Full Text
- View/download PDF
34. Distinct genetic architectures and environmental factors associate with host response to the γ2-herpesvirus infections.
- Author
-
Sallah, Neneh, Miley, Wendell, Labo, Nazzarena, Carstensen, Tommy, Fatumo, Segun, Gurdasani, Deepti, Pollard, Martin O., Dilthey, Alexander T., Mentzer, Alexander J., Marshall, Vickie, Cornejo Castro, Elena M., Pomilla, Cristina, Young, Elizabeth H., Asiki, Gershim, Hibberd, Martin L., Sandhu, Manjinder, Kellam, Paul, Newton, Robert, Whitby, Denise, and Barroso, Inês
- Subjects
EPSTEIN-Barr virus ,HERPESVIRUS diseases ,KAPOSI'S sarcoma-associated herpesvirus ,ANTIBODY formation ,INFECTION ,AFRICANS - Abstract
Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr Virus (EBV) establish life-long infections and are associated with malignancies. Striking geographic variation in incidence and the fact that virus alone is insufficient to cause disease, suggests other co-factors are involved. Here we present epidemiological analysis and genome-wide association study (GWAS) in 4365 individuals from an African population cohort, to assess the influence of host genetic and non-genetic factors on virus antibody responses. EBV/KSHV co-infection (OR = 5.71(1.58–7.12)), HIV positivity (OR = 2.22(1.32–3.73)) and living in a more rural area (OR = 1.38(1.01–1.89)) are strongly associated with immunogenicity. GWAS reveals associations with KSHV antibody response in the HLA-B/C region (p = 6.64 × 10
−09 ). For EBV, associations are identified for VCA (rs71542439, p = 1.15 × 10−12 ). Human leucocyte antigen (HLA) and trans-ancestry fine-mapping substantiate that distinct variants in HLA-DQA1 (p = 5.24 × 10−44 ) are driving associations for EBNA-1 in Africa. This study highlights complex interactions between KSHV and EBV, in addition to distinct genetic architectures resulting in important differences in pathogenesis and transmission. Disease prognosis after infection with Kaposi's sarcoma-associated herpesvirus and Epstein-Barr Virus is highly variable. Here the authors carry out epidemiological and genetic analysis of a Ugandan cohort and suggest complex interactions may influence pathogenesis and transmission. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
35. Smoking and Epstein–Barr virus infection in multiple sclerosis development.
- Author
-
Hedström, Anna Karin, Huang, Jesse, Brenner, Nicole, Butt, Julia, Hillert, Jan, Waterboer, Tim, Kockum, Ingrid, Olsson, Tomas, and Alfredsson, Lars
- Subjects
SMOKING ,EPSTEIN-Barr virus ,MULTIPLE sclerosis risk factors ,IMMUNOGLOBULINS - Abstract
It is unclear whether smoking interacts with different aspects of Epstein–Barr virus (EBV) infection with regard to multiple sclerosis (MS) risk. We aimed to investigate whether smoking acts synergistically with elevated EBNA-1 antibody levels or infectious mononucleosis (IM) history regarding MS risk. Two Swedish population-based case–control studies were used (6,340 cases and 6,219 matched controls). Subjects with different smoking, EBNA-1 and IM status were compared regarding MS risk, by calculating odds ratios (OR) with 95% confidence intervals (CI) employing logistic regression. Potential interaction on the additive scale was evaluated by calculating the attributable proportion due to interaction (AP). Current and past smokers had higher EBNA-1 antibody levels than never smokers (p < 0.0001). There was an additive interaction between current smoking and high EBNA-1 antibody levels (AP 0.3, 95% CI 0.2–0.4), but not between past smoking and high EBNA-1 antibody levels (AP 0.01, 95% CI − 0.1 to 0.1), with regard to MS risk. An interaction also occurred between current smoking and IM history (AP 0.2, 95% CI 0.004–0.4), but not between past smoking and IM history (AP − 0.06, 95% CI − 0.4 to 0.3). Current smoking increases EBNA-1 antibody levels and acts synergistically with both aspects of EBV infection to increase MS risk, indicating that there is at least one pathway to disease in which both risk factors are involved. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
36. Epstein-Barr virus reactivation in sepsis due to community-acquired pneumonia is associated with increased morbidity and an immunosuppressed host transcriptomic endotype.
- Author
-
Goh, Cyndi, Burnham, Katie L., Ansari, M. Azim, de Cesare, Mariateresa, Golubchik, Tanya, Hutton, Paula, Overend, Lauren E., Davenport, Emma E., Hinds, Charles J., Bowden, Rory, and Knight, Julian C.
- Subjects
EPSTEIN-Barr virus ,IMMUNE system ,INTENSIVE care units ,SEPSIS ,IMMUNOSUPPRESSION - Abstract
Epstein-Barr virus (EBV) reactivation is common in sepsis patients but the extent and nature of this remains unresolved. We sought to determine the incidence and correlates of EBV-positivity in a large sepsis cohort. We also hypothesised that EBV reactivation would be increased in patients in whom relative immunosuppression was the major feature of their sepsis response. To identify such patients we aimed to use knowledge of sepsis response subphenotypes based on transcriptomic studies of circulating leukocytes, specifically patients with a Sepsis Response Signature endotype (SRS1) that we have previously shown to be associated with increased mortality and features of immunosuppression. We assayed EBV from the plasma of intensive care unit (ICU) patients with sepsis due to community-acquired pneumonia. In total 730 patients were evaluated by targeted metagenomics (n = 573 patients), digital droplet PCR (n = 565), or both (n = 408). We had previously analysed gene expression in peripheral blood leukocytes for a subset of individuals (n = 390). We observed a 37% incidence of EBV-positivity. EBV reactivation was associated with longer ICU stay (12.9 vs 9.2 days; p = 0.004) and increased organ failure (day 1 SOFA score 6.9 vs 5.9; p = 0.00011). EBV reactivation was associated with the relatively immunosuppressed SRS1 endotype (p = 0.014) and differential expression of a small number of biologically relevant genes. These findings are consistent with the hypothesis that viral reactivation in sepsis is a consequence of immune compromise and is associated with increasing severity of illness although further mechanistic studies are required to definitively illustrate cause and effect. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
37. Monoamine oxidase A is down-regulated in EBV-associated nasopharyngeal carcinoma.
- Author
-
Lee, Hui Min, Sia, Alice Pei Eal, Li, Lili, Sathasivam, Hans Prakash, Chan, Melissa Sue Ann, Rajadurai, Pathmanathan, Tsang, Chi Man, Tsao, Sai Wah, Murray, Paul G., Tao, Qian, Paterson, Ian C., and Yap, Lee Fah
- Subjects
MONOAMINE oxidase ,NASOPHARYNX cancer ,METASTASIS ,EPSTEIN-Barr virus ,AMINES ,MITOCHONDRIAL enzymes - Abstract
Nasopharyngeal carcinoma (NPC) is a highly metastatic cancer that is consistently associated with Epstein-Barr virus (EBV) infection. In this study, we identify for the first time a role for monoamine oxidase A (MAOA) in NPC. MAOA is a mitochondrial enzyme that catalyzes oxidative deamination of neurotransmitters and dietary amines. Depending on the cancer type, MAOA can either have a tumour-promoting or tumour-suppressive role. We show that MAOA is down-regulated in primary NPC tissues and its down-regulation enhances the migration of NPC cells. In addition, we found that EBV infection can down-regulate MAOA expression in both pre-malignant and malignant nasopharyngeal epithelial (NPE) cells. We further demonstrate that MAOA is down-regulated as a result of IL-6/IL-6R/STAT3 signalling and epigenetic mechanisms, effects that might be attributed to EBV infection in NPE cells. Taken together, our data point to a central role for EBV in mediating the tumour suppressive effects of MAOA and that loss of MAOA could be an important step in the pathogenesis of NPC. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
38. Dasatinib exacerbates splenomegaly of mice inoculated with Epstein-Barr virus-infected lymphoblastoid cell lines.
- Author
-
Kotaki, Ryutaro, Kawashima, Masaharu, Yamamoto, Yuichiro, Higuchi, Hiroshi, Nagashima, Etsuko, Kurosaki, Natsumi, Takamatsu, Masako, Kikuti, Yara Yukie, Imadome, Ken-Ichi, Nakamura, Naoya, and Kotani, Ai
- Subjects
DASATINIB ,EPSTEIN-Barr virus ,LYMPHOBLASTOID cell lines ,CARCINOGENESIS ,DRUG efficacy - Abstract
Latent infection of Epstein-Barr virus (EBV) is associated with a poor prognosis in patients with B cell malignancy. We examined whether dasatinib, a multi kinase inhibitor, which is broadly used for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia is effective on EBV-positive B cell malignancies, using lymphoblastoid cell lines (LCLs) in vitro and in vivo. As a result, in vitro experiments showed that dasatinib induced cell death of the EBV-LCLs which was not accompanied with a lytic reactivation of EBVs. To evaluate the effectiveness in EBV latency type III represented by immunodeficiency lymphoma, LCL-inoculated immunodeficient NOD/shi-scid/Il2rg
nul (NOG) mice were treated with dasatinib. However, in vivo experiments revealed that dasatinib treatment exacerbated tumor cell infiltration into the spleen of LCL-inoculated NOG mice, whereas tumor size at the inoculated site was not affected by the treatment. These results suggest that dasatinib exacerbates the pathogenesis at least in some situations although the drug is effective in vitro. Hence, we should carefully examine a possibility of dasatinib repositioning for EBV+ B cell malignancies. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
39. Epigenetic specifications of host chromosome docking sites for latent Epstein-Barr virus.
- Author
-
Kim, Kyoung-Dong, Tanizawa, Hideki, De Leo, Alessandra, Vladimirova, Olga, Kossenkov, Andrew, Lu, Fang, Showe, Louise C., Noma, Ken-ichi, and Lieberman, Paul M.
- Subjects
EPSTEIN-Barr virus ,BURKITT'S lymphoma ,CHROMOSOMES ,DNA-binding proteins ,EPISOMES - Abstract
Epstein-Barr virus (EBV) genomes persist in latently infected cells as extrachromosomal episomes that attach to host chromosomes through the tethering functions of EBNA1, a viral encoded sequence-specific DNA binding protein. Here we employ circular chromosome conformation capture (4C) analysis to identify genome-wide associations between EBV episomes and host chromosomes. We find that EBV episomes in Burkitt's lymphoma cells preferentially associate with cellular genomic sites containing EBNA1 binding sites enriched with B-cell factors EBF1 and RBP-jK, the repressive histone mark H3K9me3, and AT-rich flanking sequence. These attachment sites correspond to transcriptionally silenced genes with GO enrichment for neuronal function and protein kinase A pathways. Depletion of EBNA1 leads to a transcriptional de-repression of silenced genes and reduction in H3K9me3. EBV attachment sites in lymphoblastoid cells with different latency type show different correlations, suggesting that host chromosome attachment sites are functionally linked to latency type gene expression programs. Epstein-Barr virus (EBV) episomes tether to the host chromosome via EBNA1. Here, using circular chromosome conformation capture (4C), Kim et al. identify attachment sites and show that EBV episomes preferentially associate with transcriptionally silenced genes in Burkitt lymphoma cells. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
40. A central role of IKK2 and TPL2 in JNK activation and viral B-cell transformation.
- Author
-
Voigt, Stefanie, Sterz, Kai R., Giehler, Fabian, Mohr, Anne-Wiebe, Wilson, Joanna B., Moosmann, Andreas, and Kieser, Arnd
- Subjects
MEMBRANE proteins ,EPSTEIN-Barr virus ,CANCER invasiveness ,INTERLEUKIN-1 ,UBIQUITINATION ,B cells - Abstract
IκB kinase 2 (IKK2) is well known for its pivotal role as a mediator of the canonical NF-κB pathway, which has important functions in inflammation and immunity, but also in cancer. Here we identify a novel and critical function of IKK2 and its co-factor NEMO in the activation of oncogenic c-Jun N-terminal kinase (JNK) signaling, induced by the latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV). Independent of its kinase activity, the TGFβ-activated kinase 1 (TAK1) mediates LMP1 signaling complex formation, NEMO ubiquitination and subsequent IKK2 activation. The tumor progression locus 2 (TPL2) kinase is induced by LMP1 via IKK2 and transmits JNK activation signals downstream of IKK2. The IKK2-TPL2-JNK axis is specific for LMP1 and differs from TNFα, Interleukin−1 and CD40 signaling. This pathway mediates essential LMP1 survival signals in EBV-transformed human B cells and post-transplant lymphoma, and thus qualifies as a target for treatment of EBV-induced cancer. IKK2 is the main mediator of the NF-kappaB pathway. Here, the authors demonstrate that LMP1 sustains the survival of Epstein-Barr virus-transformed human B cells and post-transplant lymphoma through IKK2 that induces JNK signaling through TPL2. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
41. The interaction of Multiple Sclerosis risk loci with Epstein-Barr virus phenotypes implicates the virus in pathogenesis.
- Author
-
Afrasiabi, Ali, Parnell, Grant P., Swaminathan, Sanjay, Stewart, Graeme J., and Booth, David R.
- Subjects
MULTIPLE sclerosis risk factors ,EPSTEIN-Barr virus ,PHENOTYPES ,MICRORNA ,GENE expression ,POLIOVIRUS ,THERAPEUTICS - Abstract
Translating the findings of genome wide association studies (GWAS) to new therapies requires identification of the relevant immunological contexts to interrogate for genetic effects. In one of the largest GWAS, more than 200 risk loci have been identified for Multiple Sclerosis (MS) susceptibility. Infection with Epstein-Barr virus (EBV) appears to be necessary for the development of Multiple Sclerosis (MS). Many MS risk loci are associated with altered gene expression in EBV infected B cells (LCLs). We have interrogated this immunological context to identify interaction between MS risk loci and EBV DNA copy number, intrinsic growth rate and EBV encoded miRNA expression. The EBV DNA copy number was associated with significantly more risk alleles for MS than for other diseases or traits. EBV miRNAs BART4-3p and BART3-5p were highly associated with EBV DNA copy number and MS risk loci. The poliovirus receptor (PVR) risk SNP was associated with EBV DNA copy number, PVR and miRNA expression. Targeting EBV miRNAs BART4-3p and BART3-5p, and the gene PVR, may provide therapeutic benefit in MS. This study also indicates how immunological context and risk loci interactions can be exploited to validate and develop novel therapeutic approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
42. A 5700 year-old human genome and oral microbiome from chewed birch pitch.
- Author
-
Jensen, Theis Z. T., Niemann, Jonas, Iversen, Katrine Højholt, Fotakis, Anna K., Gopalakrishnan, Shyam, Vågene, Åshild J., Pedersen, Mikkel Winther, Sinding, Mikkel-Holger S., Ellegaard, Martin R., Allentoft, Morten E., Lanigan, Liam T., Taurozzi, Alberto J., Nielsen, Sofie Holtsmark, Dee, Michael W., Mortensen, Martin N., Christensen, Mads C., Sørensen, Søren A., Collins, Matthew J., Gilbert, M. Thomas P., and Sikora, Martin
- Subjects
HUMAN genome ,HUMAN microbiota ,GENOMICS ,BIRCH ,EPSTEIN-Barr virus - Abstract
The rise of ancient genomics has revolutionised our understanding of human prehistory but this work depends on the availability of suitable samples. Here we present a complete ancient human genome and oral microbiome sequenced from a 5700 year-old piece of chewed birch pitch from Denmark. We sequence the human genome to an average depth of 2.3× and find that the individual who chewed the pitch was female and that she was genetically more closely related to western hunter-gatherers from mainland Europe than hunter-gatherers from central Scandinavia. We also find that she likely had dark skin, dark brown hair and blue eyes. In addition, we identify DNA fragments from several bacterial and viral taxa, including Epstein-Barr virus, as well as animal and plant DNA, which may have derived from a recent meal. The results highlight the potential of chewed birch pitch as a source of ancient DNA. Birch pitch is thought to have been used in prehistoric times as hafting material or antiseptic and tooth imprints suggest that it was chewed. Here, the authors report a 5,700 year-old piece of chewed birch pitch from Denmark from which they successfully recovered a complete ancient human genome and oral microbiome DNA. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
43. Epstein-Barr virus strain heterogeneity impairs human T-cell immunity.
- Author
-
Cirac, Ana, Stützle, Simon, Dieckmeyer, Michael, Adhikary, Dinesh, Moosmann, Andreas, Körber, Nina, Bauer, Tanja, Witter, Klaus, Delecluse, Henri-Jacques, Behrends, Uta, and Mautner, Josef
- Subjects
EPSTEIN-Barr virus ,T cells ,CD4 antigen ,IMMUNE system ,TUMOR treatment - Abstract
The Epstein-Barr virus (EBV) establishes lifelong infections in > 90% of the human population. Although contained as asymptomatic infection by the immune system in most individuals, EBV is associated with the pathogenesis of approximately 1.5% of all cancers in humans. Some of these EBV-associated tumors have been successfully treated by the infusion of virus-specific T-cell lines. Recent sequence analyses of a large number of viral isolates suggested that distinct EBV strains have evolved in different parts of the world. Here, we assessed the impact of such sequence variations on EBV-specific T-cell immunity. With the exceptions of EBNA2 and the EBNA3 family of proteins, an overall low protein sequence disparity of about 1% was noted between Asian viral isolates, including the newly characterized M81 strain, and the prototypic EBV type 1 and type 2 strains. However, when T-cell epitopes including their flanking regions were compared, a substantial proportion was found to be polymorphic in different EBV strains. Importantly, CD4+ and CD8+ T-cell clones specific for viral epitopes from one strain often showed diminished recognition of the corresponding epitopes in other strains. In addition, T-cell recognition of a conserved epitope was affected by amino acid exchanges within the epitope flanking region. Moreover, the CD8+ T-cell response against polymorphic epitopes varied between donors and often ignored antigen variants. These results demonstrate that viral strain heterogeneity may impair antiviral T-cell immunity and suggest that immunotherapeutic approaches against EBV should preferably target broad sets of conserved epitopes including their flanking regions. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
44. Chaetocin reactivates the lytic replication of Epstein-Barr virus from latency via reactive oxygen species.
- Author
-
Zhang, Shilun, Yin, Juan, and Zhong, Jiang
- Abstract
Oxidative stress, regarded as a negative effect of free radicals in vivo, takes place when organisms suffer from harmful stimuli. Some viruses can induce the release of reactive oxygen species (ROS) in infected cells, which may be closely related with their pathogenicity. In this report, chaetocin, a fungal metabolite reported to have antimicrobial and cytostatic activity, was studied for its effect on the activation of latent Epstein-Barr virus (EBV) in B95-8 cells. We found that chaetocin remarkably up-regulated EBV lytic transcription and DNA replication at a low concentration (50 nmol L). The activation of latent EBV was accompanied by an increased cellular ROS level. N-acetyl-L-cysteine (NAC), an ROS inhibitor, suppressed chaetocin-induced EBV activation. Chaetocin had little effect on histone H3K9 methylation, while NAC also significantly reduced H3K9 methylation. These results suggested that chaetocin reactivates latent EBV primarily via ROS pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
45. How frequently are predicted peptides actually recognized by CD8 cells?
- Author
-
Moldovan, Ioana, Targoni, Oleg, Zhang, Wenji, Sundararaman, Srividya, and Lehmann, Paul
- Subjects
PEPTIDES ,CD8 antigen ,IMMUNE response ,HLA histocompatibility antigens ,IMMUNE recognition ,EPSTEIN-Barr virus ,DETECTION limit - Abstract
Detection of antigen-specific CD8 cells frequently relies on the use of peptides that are predicted to bind to HLA Class I molecules or have been shown to induce immune responses. There is extensive knowledge on individual HLA alleles' peptide-binding requirements, and immunogenic peptides for many antigens have been defined. The 32 individual peptides that comprise the CEF peptide pool represent such well-defined peptide determinants for Cytomegalo-, Epstein-barr-, and Influenza virus. We tested the accuracy of these peptide recognition predictions on 42 healthy human donors that have been high-resolution HLA-typed. According to the predictions, 241 recall responses should have been detected in these donors. Actual testing showed that 36 (15 %) of the predicted CD8 cell responses occurred in the high frequency range, 41 (17 %) in mid-frequencies, and 45 (19 %) were at the detection limit. In 119 instances (49 %), the predicted peptides were not targeted by CD8 cells detectably. The individual CEF peptides were recognized in an unpredicted fashion in 57 test cases. Moreover, the frequency of CD8 cells responding to a single peptide did not reflect on the number of CD8 cells targeting other determinants on the same antigen. Thus, reliance on one or a few predicted peptides provides a rather inaccurate assessment of antigen-specific CD8 cell immunity, strongly arguing for the use of peptide pools for immune monitoring. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
46. De novo CpG methylation on an artificial chromosome-like vector maintained for a long-term in mammalian cells.
- Author
-
Nishioka, Keisuke, Kishida, Tsunao, Masui, Shinji, and Mazda, Osam
- Subjects
CPG nucleotides ,METHYLATION ,CELLS ,ARTIFICIAL chromosomes ,EPSTEIN-Barr virus - Abstract
Objectives: To examine whether an autonomously replicating, artificial chromosome-like vector containing a long genomic DNA sequence (namely, Epigenosome-Nanog) undergoes de novo CpG methylation after maintenance in cultured cells for more than a half year. Results: Epigenosome-Nanog efficiently replicated in iPS cells after transfection. In HeLa and C2C12 cells Epigenosome-Nanog was stably maintained for more than eight months. The CpG methylation occurred de novo at the Nanog gene promoter region on the epigenosome in C2C12 cells but the degrees of methylation were much lower than those at the same CpG sites on the chromosomes. Among the four CpG sites at the region, the upstream two CpGs underwent methylation in a correlated manner while methylation at the downstream two CpGs was also correlated to each other, and these correlations were commonly shared between the epigenosome and the chromosome. CpG methylation thus was not solely dependent on the nucleotide sequence at the DNA locus. Conclusion: The epigenosome may become a useful tool to study the mechanisms of epigenetic regulation of a genetic region of interest in mammalian cells. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
47. Case-control study of Epstein-Barr virus and Helicobacter pylori serology in Latin American patients with gastric disease.
- Author
-
Cárdenas-Mondragón, M G, Torres, J, Flores-Luna, L, Camorlinga-Ponce, M, Carreón-Talavera, R, Gomez-Delgado, A, Kasamatsu, E, and Fuentes-Pananá, E M
- Subjects
HELICOBACTER pylori infections ,GASTRIC mucosa ,EPSTEIN-Barr virus ,DISEASE progression ,ADENOCARCINOMA ,ATROPHIC gastritis ,TUMORS ,DISEASE risk factors - Abstract
Background:Chronic tissue damage induced by Helicobacter pylori (HP)-driven inflammation is considered the main risk of gastric carcinoma (GC). Epstein-Barr virus (EBV) infection has also been associated with GC. In this study, we aim to address the role of EBV in inflammatory GC precursor lesions and its added risk to HP infection.Methods:Antibodies against EBV, HP and the bacterial virulence factor CagA were measured in sera from 525 Mexican and Paraguayan patients with gastric disease. Gastric samples were characterised according to the updated Sydney classification and associations were estimated between antibody responses and severity of both tissue damage and inflammation.Results:We found significant associations (odd ratios and trends) between EBV and HP copositivity and premalignant lesions and intestinal-type GC. The EBV and HP coinfection was also significantly associated with increased infiltration of immune cells. No association was found between EBV and the less inflammation-driven diffuse-type GC.Conclusions:Our study suggests that EBV co-participates with HP to induce severe inflammation, increasing the risk of progression to intestinal-type GC. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
48. The impact of plasma epstein-barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: an observational study.
- Author
-
Tang, L-Q, Chen, Q-Y, Guo, S-S, Chen, W-H, Li, C-F, Zhang, L, Lai, X-P, He, Y, Xu, Y-X-X, Hu, D-P, Wen, S-H, Peng, Y-T, Liu, H, Liu, L-T, Yan, S-M, Guo, L, Zhao, C, Cao, K-J, Liu, Q, and Qian, C-N
- Subjects
EPSTEIN-Barr virus ,PROGNOSIS ,NASOPHARYNX cancer ,FIBRINOGEN ,BIOMARKERS ,SCIENTIFIC observation ,PHYSIOLOGY - Abstract
Background:The impact of combining plasma fibrinogen levels with Epstein-Barr Virus DNA (EBV DNA) levels on the prognosis for patients with nasopharyngeal carcinoma (NPC) was evaluated.Methods:In this observational study, 2563 patients with non-metastatic NPC were evaluated for the effects of circulating plasma fibrinogen and EBV DNA levels on disease-free survival (DFS), distant metastasis-free survival (DMFS), and overall survival (OS).Results:Compared with the bottom biomarker tertiles, TNM stage-adjusted hazard ratios (HR, 95% confidence intervals (CIs)) for predicting DFS in fibrinogen tertiles 2 to 3 were 1.26 (1.00 to 1.60) and 1.81 (1.45 to 2.26), respectively; HR for EBV DNA tertiles 2 to 3 were 1.49 (1.12 to 1.98) and 4.24 (3.27 to 5.49), respectively. After additional adjustment for established risk factors, both biomarkers were still associated (P for trend <0.001) with reduced DFS (HR: 1.79, 95% CI, 1.43 to 2.25 for top fibrinogen tertiles; HR: 4.04, 95% CI: 3.10 to 5.27 for top EBV DNA tertiles compared with the bottom tertiles). For patients with advanced-stage disease, those with high fibrinogen levels (⩾3.34 g l
−1 ) presented with worse DFS, regardless of EBV DNA ⩾4000 or <4000 copies ml−1 subgroup. Similar findings were observed for DMFS and OS.Conclusions:Circulating fibrinogen and EBV DNA significantly correlate with NPC patients survival. Combined fibrinogen and EBV DNA data lead to improved prognostic prediction in advanced-stage disease. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
49. NF-κB-mediated transcriptional upregulation of TNFAIP2 by the Epstein-Barr virus oncoprotein, LMP1, promotes cell motility in nasopharyngeal carcinoma.
- Author
-
Chen, C-C, Liu, H-P, Chao, M, Liang, Y, Tsang, N-M, Huang, H-Y, Wu, C-C, and Chang, Y-S
- Subjects
NASOPHARYNX cancer ,CANCER cell motility ,TRANSCRIPTION factors ,GENETIC regulation ,EPSTEIN-Barr virus ,STATHMIN ,NF-kappa B - Abstract
Nasopharyngeal carcinoma (NPC), which is closely associated with Epstein-Barr virus (EBV), is a metastasis-prone epithelial cancer. We previously showed that tumor necrosis factor α-induced protein 2 (TNFAIP2) is highly expressed in NPC tumor tissues and is correlated with metastasis and poor survival in NPC patients. However, the underlying mechanism remains unclear. In this study, we demonstrate that the EBV oncoprotein, latent membrane protein 1 (LMP1), can transcriptionally induce TNFAIP2 expression via NF-κB. Quantitative RT-PCR and western blotting revealed that LMP1 induces TNFAIP2 expression through its C-terminal-activating region (CTAR2) domain, which is required for transduction of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling. Inhibition of NF-κB activation or depletion of p65 (a component of NF-κB) by RNA interference abolished the LMP1-induced expression of TNFAIP2, whereas ectopic expression of p65 was sufficient to induce TNFAIP2 expression. Luciferase reporter assays showed that LMP1 transcriptionally induces TNFAIP2 expression through a newly identified NF-κB-binding site within the TNFAIP2 promoter (−3 869 to −3 860 bp). Immunohistochemical analysis of NPC biopsy specimens further revealed a significant correlation between the protein levels of TNFAIP2 and activated p65 (R=0.689, P<0.001), indicating that our findings are clinically relevant. Immunofluorescence microscopy and co-immunoprecipitation assays showed that TNFAIP2 associates with actin and is involved in the formation of actin-based membrane protrusions. Furthermore, transwell migration assays demonstrated that TNFAIP2 contributes to LMP1-induced cell motility. Collectively, these findings provide novel insights into the regulation of TNFAIP2 and its role in promoting NPC tumor progression. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
50. The cancer-virus cures.
- Author
-
Holmes, David
- Subjects
EPSTEIN-Barr virus ,HERPESVIRUSES ,ONCOGENIC DNA viruses ,EPSTEIN-Barr virus diseases - Abstract
The article discusses the discovery of the cause cancer in humans, Epstein-Barr virus (EBV). An overview about the role of EVC as the cause of over 200,000 cancers worldwide each year is provided. The virus, which was discovered by, Michael Anthony Epstein, Yvonne Barr and Bert Achong, is said to turn conventional virological and oncological wisdom on its head.
- Published
- 2014
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.